YOUR SEARCH FOR Text 221 RESULTS
91 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key …
92 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key …
93 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… Press Release View all news Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial …
94 of Total
Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Ass
… Press Release View all news Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at …
95 of Total
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with
… … Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with …
96 of Total
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults wi
… … Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults wi …
97 of Total
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in
… … Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in …
98 of Total
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the Eu
… … Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the Eu …